Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link. <http://hdl.handle.net/2066/190689>

Please be advised that this information was generated on 2019-12-04 and may be subject to change.

Article 25fa pilot End User Agreement

This publication is distributed under the terms of Article 25fa of the Dutch Copyright Act (Auteurswet) with explicit consent by the author. Dutch law entitles the maker of a short scientific work funded either wholly or partially by Dutch public funds to make that work publicly available for no consideration following a reasonable period of time after the work was first published, provided that clear reference is made to the source of the first publication of the work.

This publication is distributed under The Association of Universities in the Netherlands (VSNU) 'Article 25fa implementation' pilot project. In this pilot research outputs of researchers employed by Dutch Universities that comply with the legal requirements of Article 25fa of the Dutch Copyright Act are distributed online and free of cost or other barriers in institutional repositories. Research outputs are distributed six months after their first online publication in the original published version and with proper attribution to the source of the original publication.

You are permitted to download and use the publication for personal purposes. All rights remain with the author(s) and/or copyrights owner(s) of this work. Any use of the publication other than authorised under this licence or copyright law is prohibited.

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please contact the Library through email: copyright@ubn.ru.nl, or send a letter to:

University Library Radboud University Copyright Information Point PO Box 9100 6500 HA Nijmegen

You will be contacted as soon as possible.

Library Synthesis in Flow

Continuous Flow Synthesis of Urea-Containing Compound Libraries Based on the Piperidin-4-one Scaffold

Alejandra Riesco-Domínguez,^[a] Daniel Blanco-Ania,^[a] and Floris P. J. T. Rutjes^{*[a]}

Abstract: The advantages of performing reactions in continuous flow vs. the classic batch processes render flow chemistry a suitable technique for library synthesis. Inspired by our recent work to create fluorine-containing nitrogen heterocycles and

Introduction

The urea group represents an important functionality in pharmaceutical and agrochemical products.^[1] Urea-containing molecules possess an immense potential in drug design as a result of their capability for hydrogen binding to biomolecular targets.^[2] Moreover, ureas are widely used in drug design for the modulation of several factors, such as selectivity, stability, toxicity and pharmacokinetic profile of lead molecules.^[2] Examples of active compounds containing a urea unit are depicted in Figure 1. Trimefluor,^[3] a selective pre- and post-emergence herbicide for use in cotton, and triflumuron,^[4] a broad spectrum insecticide against chewing insects commercialized by Bayer CropScience, are examples of bioactive molecules containing a urea group. Another example of a urea-containing pharmaceutical is vestipitant,^[5] a selective antagonist for the NK₁ receptor.

Figure 1. Biologically active compounds containing a urea group.

Recently, we reported an enantio- and diastereoselective synthesis of piperidin-4-ones **2a**–**c** from the enantiopure amino ketone **1** (Scheme 1).[6] Compounds **2a**–**c**, containing three different fluorine functionalities (F, CF_3 and SF_5) to enhance their bioactivity and metabolic profile, $[7]$ were synthesized and further derivatized into a novel library of spirocyclic compounds

available on the WWW under https://doi.org/10.1002/ejoc.20170153[9.](https://doi.org/10.1002/ejoc.201701539)

by the potential of the urea group in drug design, we herewith describe the combination of both aspects in the continuous flow synthesis of two libraries of urea derivatives based on the piperidin-4-one scaffold.

(**3** and **4**) under classic batch processes through a diastereoselective Pictet–Spengler cyclization.^[6]

Scheme 1. Previously reported work (batch) and this work (flow) based on scaffolds **2a**–**c**.

The inherent potential of this scaffold (**2a**–**c**) for derivatization combined with the advantages of flow chemistry for library synthesis^[8] (including excellent heat exchange and fast mixing for better reaction control, automated small-scale optimization and rapid automated compound-library preparation) encouraged us to further develop a new class of urea derivatives in flow (**5** and **6**) based on scaffolds **2a**–**c** (Scheme 1).

Results and Discussion

We started our investigations by testing the reactivity of our amines (**2b** and **2c**) with alkyl isocyanates (ethyl [**7A**] or isopropyl isocyanate [**7B**], 1.5 equiv.) varying solvent, temperature and reaction time (see Table 1 for summarized results and Supporting Information [SI] for the entire optimization process). All reactions were carried out in a borosilicate glass reactor (channel width 600 μm, channel depth 500 μm and effective reactor volume 100 μL).[9] The microreactor was placed into a microreactor holder, which automatically aligns with the fluidic connections and makes contact with the temperature controlled

Supporting information and ORCID(s) from the author(s) for this article are O

metal plate in the microreactor holder. Then, the inlet modules were connected through the microreactor holder with the inlet ports of the microreactor and the outlet tubing was also placed at the outlet port. The tubing was connected to the syringes, which were connected to the pumps. The two solutions, one containing the piperidin-4-ones (**2b** or **2c**) and the other one with the isocyanates **7** were pumped and brought together inside of the microreactor (Table 1). Initially, we used solvents such as MeCN or 1,2-dichloroethane in a temperature range of 50–80 °C and reaction times of 10–15 minutes (entries 1–4). Low conversions to ureas **5bA** and **5bB** were obtained in all these cases and only a slightly higher conversion to **5bA** (ratio **5bA**/**2b** 1:0.7) was achieved when we used MeCN at 50 °C (entry 1). The use of EtOH at 80 °C and a reaction time of 10 minutes provided a ratio of 1:1.2 for **5bB**/**2b** (entry 5). An increase of the reaction time to 15 minutes (entry 6) gave higher conversion into product **5bB** (1:0.15). By increasing the amount of isocyanate (2.0 and 2.5 equiv., entries 7 and 8, respectively), nearly full conversion to **5bB** and full conversion to **5cA** were obtained. However, carbamate **8** was also formed in the reaction mixture when EtOH was used as solvent, as a result of the nucleophilic attack of EtOH to the isocyanate. Therefore, we explored the use of bulkier alcohols as solvent (iPrOH and tBuOH) to avoid the formation of **8**. Thus, the reaction of piperidin-4-one **2c** with ethyl isocyanate (2.5 equiv.) in the presence of propan-2-ol gave full conversion to urea **5cA** and less formation of the carbamate **8** (entry 9) whereas the formation of **8** was completely suppressed when tert-butyl alcohol was used (entry 10).[10] With this result in hands, we tried to decrease the temperature of the reaction and the amount of isocyanate used. We confirmed that when using 2.0 equiv. of ethyl isocyanate and temperatures between 25–35 °C full conversion was not reached (entries 11 and 12). Finally, we found that the use of 2.0 equiv. of ethyl isocyanate at 50 °C in tBuOH were the suitable conditions to obtain full conversion to compound **5cA** (entry 13). Once the conditions for the synthesis of aliphatic ureas were optimized, we attempted the synthesis of the aryl derivatives. Therefore, we first explored the reaction of **2b** with 2,4-difluorophenyl isocyanate (**7E**, 1.5 equiv.) at 80 °C in EtOH and a reaction time of 20 minutes; the reaction, however, did not show any conversion to product **5bE** and it resulted in a mixture of **2b** and carbamate **8** (ratio **2b**/**8d** 1:0.50; entry 14).

By changing the solvent to 1,2-dichloroethane, and using 1.3 equiv. of isocyanate **7E**, full conversion to compound **5bE** was obtained (entry 15).

With the final conditions in hands, five isocyanates **7A**–**E** (alkyl and aryl isocyanates with different substituents on the phenyl ring, Figure 2) were selected for the generation of a 15 compound library (Table 2). For all experiments, three fractions (stabilization time, collected product and residual) were collected in separated vials and final products were analyzed di-

Figure 2. Isocyanates used for the generation of the library.

Table 1. Optimization process for the synthesis of alkyl and aryl ureas **5b** and **5c**.

[a] Calculated by ¹H NMR of the fraction of the collected product. [b] Analyzed by ¹H NMR of the fraction of stabilization time.

Table 2. Library of ureas **5aA**–**cE** based on the piperidin-4-one scaffold.

[a] Reaction carried out in tBuOH at 50 °C in 17 minutes using 2.0 equiv. of isocyanate. [b] Reaction carried out in 1,2-dicloroethane at 80 °C in 17 min using 1.3 equiv. of isocyanate. [c] Conversion calculated by ¹H NMR of the fraction of collected product. [d] Isolated yield of the fraction of collected product.

rectly by ¹H NMR from the fraction of collected product. This fraction always started after running three cycles of the stabilization time (see [SI] for experimental details).^[12]

The reaction of piperidin-4-ones **2a**–**c** with alkyl isocyanates **7A** and **7B** gave full conversions to products **5aA**–**cB** in very good to excellent yields (83–92 %).

We also obtained full conversions to ureas **5aC**–**cE** when aryl isocyanates (**7C**–**E**) were used. Very good to excellent yields were obtained for compounds **5aC**, **5aE**, **5bC** and **5cC**–**cE**. Good yields were obtained for compounds **5aD** and **5bD** whereas compound **5bE** was obtained with a moderate yield. The excess of isocyanates was removed in vacuo as much as possible so that only small amounts of the least volatile isocyanates remained in the reaction mixtures. The crude mixtures of compounds **5bA** and **5bB** showed the presence of a minor product in a 1:0.1 ratio according to their ¹H NMR spectra. We attributed these mixtures to be either rotamers of the urea group or a possible mixture of atropisomers, with the carbamoyl group (almost) perpendicular to the piperidine ring (Figure 3), both caused by the congested 2,6-diphenylpiperidine-1-carboxamide framework. For ureas **5bC** and **5bD**, the ratio of the isomers could not be measured accurately whereas for the rest of ureas only one of both isomers was observed.

Figure 3. Rotamers and atropisomers of **5bA** and **5bB**.

Optimization of these reactions to obtain full conversion was crucial because no further column chromatography was required. Purifying these poorly soluble ureas generally requires polar solvents such as MeOH, but in case of sterically congested

ureas methanolysis^[13] may take place in the purification process. In this case, methanolysis occurred because the nitrogen in the piperidine ring might not be fully conjugated anymore with the carbonyl and therefore MeOH can form a hydrogen bond with the nitrogen. To analyze the reactivity of these ureas in MeOH, we dissolved urea **5aC** in CD₃OD and monitored the mixture by ¹H NMR (Scheme 2). We observed that compound **5aC** was still present after 1–4 h, but after 19 h at room temperature compound **5aC** transformed into piperidin-4-one **2a** (protonated and deuterated substrates), phenyl isocyanate **7C** and carbamates **9** and **10** (relative abundance **9**/**10** 30:70). ¹ H NMR showed a mixture of compounds which was confirmed by GC–MS (Scheme 2).

Scheme 2. Methanolysis of ureas **5aC** and **5cB**.

We also studied the decomposition of the aliphatic urea **5cB**, which also showed the presence of carbamates **9** and **10** (detected by GC–MS) and the starting material **2c** (protonated and deuterated substrates).

Finally, a diastereoselective reduction of ketone **2c** was carried out in flow using $LiBH₄$ as reducing reagent to provide full conversion to a 10:1 mixture of piperidinols **11** and **12** (Scheme 3). The workup of this reaction was performed offline after the reaction mixture was completely collected in the corresponding vial. The reduction of ketone **2b** was performed in batch using N-Selectride^[14] to give alcohol 12.^[15]

Scheme 3. Reduction of 2a and 2c with N-Selectride and LiBH₄.

Then, we decided to perform the urea synthesis using as starting material amino alcohol **11** (Table 3). Initially, we performed the reaction between **11** and isocyanate **7B** using the conditions previously developed for aliphatic isocyanates (tBuOH, 17 min and 50 °C). We decreased the amount of **7B** to 1.0 equiv., to firstly test the reactivity of our hindered amine in the presence of the nucleophilic alcohol. We confirmed by ¹H NMR that only the amine group reacted with the isocyanate and therefore the corresponding carbamate was not observed. However, while using 1.0 equiv. of isocyanate, a ratio **11**/**6b** 1:0.5 was obtained. Thus, we increased the amount of isocyanate **7B** to 1.5 equiv. and full conversion to urea **6b** was achieved (84 % yield). When we applied these conditions using ethyl (**7A**) and benzyl (**7F**) isocyanates, amino alcohol **11** was converted with full conversion to ureas **6a** and **6c**[16] in 85 and 99 % yield, respectively. Finally, two additional examples with aryl isocyanates (**7C** and **7D**) were synthesized. In this case, the use of 1.1 equiv. of isocyanate in 1,2-DCE at 80 °C was sufficient to reach full conversion to ureas **6d** and **6e**. For compounds **6a**– **e**, a 6:1 ratio of conformers was obtained.

Table 3. Library of ureas **6a**–**e** based on amino alcohol **11**.

[a] Reaction carried out in tBuOH at 50 °C in 17 min using 1.5 equiv. of isocyanate. [b] Reaction carried out in 1,2-dicloroethane at 80 °C in 17 min using 1.1 equiv. of isocyanate. [c] Conversion calculated by ¹H NMR of the fraction of collected product. [d] Isolated yield of the fraction of collected product.

As previously mentioned, the presence of the conformers (rotamers or atropisomers) was caused by the hindered rotation around one of the single N-CO bonds of the urea.[17] NOESY experiments of compound **13a** (the major product of reaction between alcohol **12** and isocyanate **7B**) showed correlations between the NH of the urea with both benzylic protons (Table 4), indicating therefore the existence of atropisomerism (in case of rotamers, each rotamer would show only one corre-

Table 4. Chemical shifts [ppm] of atropisomers 13a and 13b in CDCl₃.

lation with one benzylic proton).^[18] The assignment of the characteristic protons is depicted in Table 4. Chemical shifts of compounds **13a** and **13b**[19] present a considerable difference, not only for the benzylic protons H^2 and H^6 (entries 1 and 5), but also for protons H^4 and H^7 (entries 3 and 6). We were also able to confirm that the major product of the stereoisomers was compound **13a**, which showed a correlation between the NH proton of the urea and both benzylic protons, H^2 and H^6 . The clarification of these two products was done by NOESY studies.

Conclusions

In summary, we have synthesized a small library of ureas in continuous flow. The reactions utilized for their syntheses were achieved in a reaction time of 17 min without further need of purification rendering drug-like molecules. Moreover, we have also diastereoselectively reduced the ketone group in flow in 3 min reaction time. Additional urea formation of amino alcohol **11** was also performed to create five different urea derivatives. NMR studies confirmed the formation of conformers caused by the hindered rotation around one of the single N–CO bonds of the urea. The elucidation of these species to be identified as either rotamers or atropisomers could not be clarified. This methodology could be applied to a wide range of substrates as a tool to prepare libraries of potentially bioactive molecules.

Experimental Section

General Information: Reagents were obtained from commercial suppliers and were used without purification. Standard syringe techniques were applied for the transfer of dry solvents and air- or moisture-sensitive reagents. Reactions were followed by ¹H NMR, and R_F values were obtained, using thin layer chromatography (TLC) on silica gel-coated plates (Merck 60 F254) with the indicated solvent mixture. Detection was performed with UV light, and/or by charring at ca. 150 °C after dipping into a solution of $KMD₄$. Infrared spectra were recorded on an IR-ATR Bruker TENSOR 27 spectrometer. High-resolution or accurate mass measurement (ΔM < 3mmu or 5 ppm) were recorded on a JEOL AccuTOF-CS JMS-T100CS for Electrospray (spectra recorded in infusion in MeOH containing 50 nm PPG-475 as internal mass-drift compensation standard) or JEOL AccuTOF-GCv JMS-T100GCv (GC/Electron Ionization MS, column bleeding at high temperature used as internal mass drift compensation standard) for methanolysis experiments. NMR spectra were recorded at 298 K on a Varian Inova 400 (400 MHz), Bruker Avance III 400 MHz or Bruker Avance III 500 MHz spectrometer in the solvent indicated. Chemical shifts are given in parts per million (ppm) with respect to tetramethylsilane (δ =0.00 ppm) as internal standard for ¹H NMR; and CDCl₃ (δ =77.16 ppm) as internal standard for ¹³C NMR spectroscopy. Coupling constants are reported as J values in Hertz [Hz]. ¹H NMR spectroscopic data are reported as follows: chemical shift (ppm), multiplicity ($s = singlet$, $d =$ doublet, $dd =$ doublet of doublets, $dt =$ doublet of triplets, $dq =$ doublet of quartets, ddd = doublet of doublet of doublets, quint = quintet, $t =$ triplet, $dd =$ triplet of doublets, $m =$ multiplet), coupling constants [Hz], and integration. Compounds were fully characterized by ¹H, ¹³C, COSY, HSQC, HMBC and NOESY. Reactions were carried out using the FlowStart Evo equipment and microreactors purchased by FutureChemistry (futurechemistry.com accessed Sep 11, 2017). At very low flow rates, stabilization and pressure

of the equipment may take long; therefore, a stabilization time is calculated and run before the collecting product fraction. The stabilization time is calculated following Equation (1) :^[12]

Stabilization Time = $3 \times$ Reactor Volume/Total Flow Rate (1)

For all reactions, products were analyzed from the collected fraction and therefore calculations and yields and based on this fraction.

General Procedure for the Synthesis of Alkyl Ureas 5aA, 5aB, 5bA, 5bB, 5cA and 5cB: Solution A: piperidin-4-one (**2a**–**c**, 1.0 equiv.) dissolved in tBuOH (99.8-100.2 mm). Solution B: alkyl isocyanate (**7A** or **7B**, 2.0 equiv.) dissolved in tBuOH (0.1 M). Solution A (1.96 μL/min) was combined with B (3.92 μL/min) inside the glass microreactor (internal volume: 100 μL). The reaction was performed at 50 °C for 17 min.

(2*S***,6***R***)-2-(3,4-Dimethoxyphenyl)-***N***-ethyl-6-(4-fluorophenyl)-4 oxopiperidine-1-carboxamide (5aA):** According to the general procedure, the reaction of piperidin-4-one 2a (3.63 mg, 0.011 mmol) in tBuOH (99.8 mM) with **7A** afforded urea **5aA** (3.67 mg, 9.16 μmol). ¹ H NMR (400 MHz, CDCl3): *δ* = 7.39–7.31 (m, 2 H), 7.08–7.01 (m, 2 H), 6.80 (d, $J = 8.2$ Hz, 1 H), 6.75 (dd, $J = 8.2$, 2.1 Hz, 1 H), 6.64 (d, $J = 2.1$ Hz, 1 H), 6.00 (t, $J = 5.4$ Hz, 1 H), 5.22 $(dd, J = 9.7, 4.9 Hz, 1 H), 4.40 (t, J = 5.2 Hz, 1 H), 3.86 (s, 3 H), 3.73$ $(s, 3 H)$, 3.18–3.07 (m, 3 H), 2.88–2.73 (m, 2 H), 2.60 (dd, $J = 17.6$, 4.9 Hz, 1 H), 0.88 (t, $J = 7.2$ Hz, 3 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 207.8, 162.1 (d, J = 247.5 Hz), 159.1, 150.1, 149.0, 139.0 (d, J = 3.1 Hz), 134.9, 128.4 (d, $J = 8.0$ Hz), 117.9, 116.0 (d, $J = 21.5$ Hz), 111.4, 108.9, 56.1, 56.0, 52.4, 46.1, 43.6, 36.2, 15.2 ppm. FTIR: $\tilde{v} =$ 3420, 2967, 1722, 1639, 1511, 1264, 1228, 1025 cm–1. **HRMS** [ESI (m/z)] calcd. for $(C_{22}H_{25}FN_2O_4 + Na)^+ = 423.16906$, found 423.16916 (|Δ| = 1.0 ppm). *R***F**: 0.27 (heptane/AcOEt, 1:2). **Yield**: 83 %.

(2*S***,6***R***)-2-(3,4-Dimethoxyphenyl)-***N***-ethyl-4-oxo-6-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide (5bA):** According to the general procedure, the reaction of piperidin-4-one **2b** (4.68 mg, 0.012 mmol) in tBuOH (100.2 mM) with **7A** afforded urea **5bA** (4.74 mg, 0.011 mmol). ¹ H NMR (400 MHz, CDCl3): *δ* = 7.66–7.60 (m, 2 H), 7.56–7.51 (m, 2 H), 6.80 (d, $J = 8.2$ Hz, 1 H), 6.75 (ddd, $J = 8.2$, 2.1, 0.5 Hz, 1 H), 6.54 (d, $J = 2.1$ Hz, 1 H), 6.20 (t, $J = 5.2$ Hz, 1 H), 5.12 (dd, $J = 10.2$, 4.9 Hz, 1 H), 4.44 (t, $J = 5.2$ Hz, 1 H), 3.86 (s, 3 H), 3.67 (s, 3 H), 3.23-3.11 (m, 3 H), 2.86 (dd, $J = 18.4$, 5.6 Hz, 1 H), 2.74 $(dd, J = 17.5, 10.2$ Hz, 1 H), 2.61 $(dd, J = 17.5, 4.9$ Hz, 1 H), 0.90 $(t,$ $J = 7.2$ Hz, 3 H) ppm. ¹³C NMR (101 MHz, CDCl₃): $\delta = 207.2$, 159.1, 150.3, 149.2, 147.4, 134.6, 129.9 (indirect observation), 127.3, 126.1 $(q, J = 3.6$ Hz), 124.0 $(q, J = 272.2$ Hz), 117.9, 111.5, 108.7, 56.6, 56.1, 56.0, 52.3, 46.6, 42.9, 36.2, 15.2 ppm. FTIR: \tilde{v} = 3422, 2970, 1722, 1635, 1517, 1327, 1264, 1238, 1123, 725 cm–1. **HRMS** [ESI (m/z)] calcd. for $(C_{23}H_{25}F_3N_2O_4 + Na)^+$ = 473.16586, found 473.16547 ($|\Delta|$ = 2.0 ppm). *R***F**: 0.28 (heptane/AcOEt, 1:2). **Yield**: 85 %.

(2*S***,6***R***)-2-(3,4-Dimethoxyphenyl)-***N***-ethyl-4-oxo-6-[4-(pentafluoro–λ6-sulfanyl)phenyl]piperidine-1-carboxamide (5cA):** According to the general procedure, the reaction of piperidin-4-one **2c** (2.21 mg, 5.05 μmol) in tBuOH (99.9 mM) with **7A** afforded urea **5cA** (2.37 mg, 4.66 µmol). ¹H NMR (400 MHz, CDCl₃): δ = 7.81-7.71 (m, 2 H), 7.55–7.49 (m, 2 H), 6.80 (d, $J = 8.2$ Hz, 1 H), 6.76 (dd, $J =$ 8.2, 2.0 Hz, 1 H), 6.48 (d, $J = 2.0$ Hz, 1 H), 6.25 (t, $J = 5.1$ Hz, 1 H), 5.07 (dd, $J = 10.3$, 5.0 Hz, 1 H), 4.47 (t, $J = 5.2$ Hz, 1 H), 3.86 (s, 3 H), 3.66 (s, 3 H), 3.24–3.09 (m, 3 H), 2.88 (dd, $J = 18.5$, 5.8 Hz, 1 H), 2.72 $(dd, J = 17.6, 10.4 \text{ Hz}, 1 \text{ H}$, 2.61 (dd, $J = 17.6, 5.0 \text{ Hz}, 1 \text{ H}$), 0.91 (t, $J = 7.2$ Hz, 3 H) ppm. ¹³C NMR (101 MHz, CDCl₃): $\delta = 206.9$, 159.0, 153.1 (indirect observation), 150.4, 149.2, 147.2 (indirect observation), 134.4, 127.3, 126.7 (indirect observation), 117.9, 111.5, 108.5, 56.8, 56.1, 55.9, 51.9, 46.8, 42.7, 36.3, 15.2 ppm. FTIR: $\tilde{\text{v}}$ = 3431, 2925,

1723, 1643, 1518, 1264, 1239, 844 cm–1. **HRMS** [ESI (m/z)] calcd. for $(C_{22}H_{25}F_5N_2O_4S + Na)^+ = 531.13474$, found 531.13535 ($|\Delta|$ = 0.1 ppm). *R***F**: 0.26 (heptane/AcOEt, 1:2). **Yield**: 92 %.

(2*S***,6***R***)-2-(3,4-Dimethoxyphenyl)-6-(4-fluorophenyl)-***N***-isopropyl-4-oxopiperidine-1-carboxamide (5aB):** According to the general procedure, the reaction of piperidin-4-one **2a** (3.50 mg, 0.01 mmol) in tBuOH (99.8 mM) with **7B** afforded **5aB** (3.72 mg, 8.98 μmol). ¹H NMR (400 MHz, CDCl₃): δ = 7.40–7.31 (m, 2 H), 7.09– 7.00 (m, 2 H), 6.80 (d, $J = 8.2$ Hz, 1 H), 6.75 (ddd, $J = 8.2$, 2.1, 0.6 Hz, 1 H), 6.67 (d, $J = 2.1$ Hz, 1 H), 5.95 (t, $J = 5.5$ Hz, 1 H), 5.23 (dd, $J =$ 9.6, 4.9 Hz, 1 H), 4.29 (d, J = 7.2 Hz, 1 H), 3.88-3.80 (m, 1 H), 3.86 (s, 3 H), 3.74 (s, 3 H), 3.10 (dd, $J = 18.2$, 5.5 Hz, 1 H), 2.83 (dd, $J = 17.7$, 9.5 Hz, 1 H), 2.79 (dd, $J = 18.2$, 5.9 Hz, 1 H), 2.61 (dd, $J = 17.6$, 4.9 Hz, 1 H), 0.94 (d, $J = 6.5$ Hz, 3 H), 0.83 (d, $J = 6.5$ Hz, 3 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 207.8, 162.2 (d, J = 247.3 Hz), 158.4, 150.2, 149.0, 139.1 (d, $J = 3.2$ Hz), 135.1, 128.5 (d, $J = 8.0$ Hz), 117.9, 116.0 $(d, J = 21.4 \text{ Hz})$, 111.4, 109.1, 56.1, 55.9, 52.5, 46.0, 43.7, 43.2, 23.3, 23.0 ppm. FTIR: \tilde{v} = 3420, 2969, 1721, 1639, 1605, 1510, 1263, 1228, 1026, 854 cm⁻¹. **HRMS** [ESI (m/z)] calcd. for $(C_{23}H_{27}FN_{2}O_4 + Na)^+$ = 437.18471, found 437.18465 (|Δ| = 1.4 ppm). *R***F**: 0.41 (heptane/ AcOEt, 1:2). **Yield**: 84 %.

(2*S***,6***R***)-2-(3,4-Dimethoxyphenyl)-***N***-isopropyl-4-oxo-6-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide (5bB):** According to the general procedure, the reaction of piperidin-4-one **2b** (4.10 mg, 0.01 mmol) in tBuOH (100.2 mM) with **7B** afforded **5bB** $(4.48 \text{ mg}, 9.65 \text{ µmol})$. ¹H NMR (400 MHz, CDCl₃): $\delta = 7.66 - 7.60 \text{ (m, m)}$ 2 H), 7.57-7.51 (m, 2 H), 6.80 (d, $J = 8.2$ Hz, 1 H), 6.75 (ddd, $J = 8.2$, 2.2, 0.5 Hz, 1 H), 6.55 (d, $J = 2.1$ Hz, 1 H), 6.16 (t, $J = 5.2$ Hz, 1 H), 5.11 (dd, $J = 10.2$, 4.9 Hz, 1 H), 4.33 (d, $J = 7.2$ Hz, 1 H), 3.88-3.82 $(m, 1 H)$, 3.86 (s, 3 H), 3.68 (s, 3 H), 3.18 (dd, $J = 18.4$, 4.7 Hz, 1 H), 2.87 (dd, $J = 18.4$, 5.7 Hz, 1 H), 2.74 (dd, $J = 17.5$, 10.2 Hz, 1 H), 2.61 $(dd, J = 17.5, 4.9$ Hz, 1 H), 0.97 $(d, J = 6.5$ Hz, 3 H), 0.82 $(d, J = 6.5$ Hz, 3 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 207.2, 158.3, 150.3, 149.2, 147.5, 134.8, 129.9 (indirect observation), 127.3, 126.1 (q, J = 3.6 Hz), 122.5 (indirect observation), 117.9, 111.5, 108.7, 56.5, 56.1, 56.0, 52.3, 46.5, 43.3, 42.9, 23.3, 23.0 ppm. FTIR: \tilde{v} = 3417, 2968, 1722, 1642, 1516, 1326, 1262, 1238, 1123, 767 cm–1. **HRMS** [ESI (m/z)] calcd. for $(C_{24}H_{27}F_3N_2O_4 + Na)^+$ = 487.18151, found 487.18134 ($|\Delta|$ = 1.5 ppm). *R***F**: 0.41 (heptane/AcOEt, 1:2). **Yield**: 89 %.

(2*S***,6***R***)-2-(3,4-Dimethoxyphenyl)-***N***-isopropyl-4-oxo-6-[4- (pentafluoro–λ6-sulfanyl)phenyl]piperidine-1-carboxamide (5cB):** According to the general procedure, the reaction of piperidin-4-one **2c** (4.76 mg, 0.01 mmol) in tBuOH (99.9 mM) with **7B** afforded **5cB** (5.22 mg, 9.99 μmol). ¹H NMR (400 MHz, CDCl₃): δ = 7.78–7.73 (m, 2 H), 7.56–7.50 (m, 2 H), 6.80 (d, J = 8.2 Hz, 1 H), 6.75 $(dd, J = 8.2, 2.1 Hz, 1 H$, 6.49 $(d, J = 2.1 Hz, 1 H)$, 6.22 $(t, J = 5.1 Hz,$ 1 H), 5.04 (dd, J = 10.4, 5.0 Hz, 1 H), 4.36 (d, J = 7.2 Hz, 1 H), 3.86 (s, 3 H), 3.66 (s, 3 H), 3.18 (dd, $J = 18.4$, 4.3 Hz, 1 H), 2.89 (dd, $J =$ 18.4, 5.7 Hz, 1 H), 2.71 (dd, $J = 17.5$, 10.4 Hz, 1 H), 2.60 (dd, $J = 17.5$, 5.0 Hz, 1 H), 0.99 (d, $J = 6.5$ Hz, 3 H), 0.82 (d, $J = 6.5$ Hz, 3 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 206.9, 158.3, 152.9 (indirect observation), 150.4, 149.3, 147.4, 134.6, 127.3, 126.8–126.6 (m), 117.9, 111.5, 108.5, 56.8, 56.2, 55.9, 51.8, 46.8, 43.3, 42.6, 23.3, 23.0 ppm. FTIR: \tilde{v} = 3421, 2970, 1723, 1642, 1517, 1263, 1238, 842 cm⁻¹. **HRMS** [ESI (m/z)] calcd. for $(C_{23}H_{27}F_5N_2O_4S + Na)^+ = 545.15039$, found 545.15003 ($|\Delta|$ = 1.7 ppm). R_F : 0.45 (heptane/AcOEt, 1:2). **Yield**: 92 %.

Synthesis and Full Characterization of Aryl Ureas 5aC–aE, 5bC– bE and 5cC–cE: Solution A: piperidin-4-one (**2a**–**c**, 1.0 equiv.) dissolved in 1,2-DCE (78.5–102.5 mM). Solution B: aryl isocyanate (**7C**, **7D** or **7E**, 1.3 equiv.) dissolved in 1,2-DCE (0.1 M). Solution A (2.56 μL/min) was combined with B (3.32 μL/min) inside the glass microreactor (internal volume: 100 μL). The reaction was performed at 80 °C for 17 min.

(2*S***,6***R***)-2-(3,4-Dimethoxyphenyl)-6-(4-fluorophenyl)-4-oxo-***N***phenylpiperidine-1-carboxamide (5aC):** According to the general procedure, the reaction of piperidin-4-one **2a** (2.59 mg, 7.86 μmol) in 1,2-DCE (88.9 m_M) with **7C** afforded **5aC** (3.15 mg, 7.02 μmol). ¹H NMR (400 MHz, CDCl₃): δ = 7.45–7.38 (m, 2 H), 7.25–7.18 (m, 2 H), 7.12–7.05 (m, 2 H), 7.05–6.98 (m, 3 H), 6.89–6.83 (m, 2 H), 6.65 (d, $J = 1.7$ Hz, 1 H), 6.60 (s, 1 H), 6.19 (t, $J = 5.3$ Hz, 1 H), 5.35 (dd, $J =$ 10.1, 4.9 Hz, 1 H), 3.89 (s, 3 H), 3.72 (s, 3 H), 3.21 (dd, $J = 18.4$, 4.9 Hz, 1 H), 2.95-2.85 (m, 2 H), 2.67 (dd, $J = 17.6$, 4.9 Hz, 1 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 207.2, 162.3 (d, J = 247.8 Hz), 156.6, 150.6, 149.5, 138.6, 138.5 (d, $J = 3.4$ Hz), 134.3, 129.1, 128.6 (d, $J =$ 8.0 Hz), 123.7, 120.0, 118.1, 116.3 (d, J = 21.4 Hz), 111.7, 108.9, 56.6, 56.2, 56.1, 52.3, 46.3, 43.4 ppm. FTIR: \tilde{v} = 3388, 2924, 1722, 1662, 1510, 1265, 1235, 1026, 754 cm–1. **HRMS** [ESI (m/z)] calcd. for $(C_{26}H_{25}FN_{2}O_{4} + Na)^{+} = 471.16906$, found 471.16910 ($|\Delta| = 1.1$ ppm). *R***F**: 0.24 (heptane/AcOEt, 2:1). **Yield**: 89 %.

(2*S***,6***R***)-2-(3,4-Dimethoxyphenyl)-4-oxo-***N***-phenyl-6-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide (5bC):** According to the general procedure, the reaction of piperidin-4-one **2b** (2.1 mg, 5.54 μmol) in 1,2-DCE (82.8 mM) with **7C** afforded **5bC** (2.43 mg, 4.87 μmol). ¹H NMR (400 MHz, CDCl₃): δ = 7.69-7.64 (m, 2 H), 7.62–7.57 (m, 2 H), 7.25–7.19 (m, 2 H), 7.06–6.99 (m, 3 H), 6.89– 6.85 (m, 2 H), 6.64 (s, 1 H), 6.53-6.51 (m, 1 H), 6.41 (t, $J = 5.0$ Hz, 1 H), 5.22 (dd, J = 10.8, 4.8 Hz, 1 H), 3.89 (s, 3 H), 3.65 (s, 3 H), 3.29 $(dd, J = 18.6, 4.1 Hz, 1 H$), 2.98 (dd, $J = 18.6, 5.8 Hz, 1 H$), 2.80 (dd, $J = 17.5$, 10.8 Hz, 1 H), 2.66 (dd, $J = 17.5$, 4.8 Hz, 1 H) ppm. ¹³C NMR (101 MHz, CDCl3): *δ* = 206.6, 156.7, 150.7, 149.7, 146.7, 138.5, 133.9, 130.2 (indirect observation), 129.1, 127.4, 126.2 (q, J = 3.6 Hz), 125.9 (indirect observation), 123.9, 120.0, 118.1, 111.7, 108.6, 57.3, 56.2, 56.0, 51.9, 46.9, 42.6 ppm. FTIR: $\tilde{\text{v}}$ = 3391, 2939, 1722, 1663, 1597, 1517, 1442, 1327, 1265, 1238, 755 cm–1. **HRMS** [ESI (m/z)] calcd. for $(C_{27}H_{25}F_3N_2O_4 + Na)^+$ = 521.16586, found 521.16560 ($|\Delta|$ = 1.6 ppm). *R***F**: 0.70 (heptane/AcOEt, 1:2). **Yield**: 88 %.

(2*S***,6***R***)-2-(3,4-Dimethoxyphenyl)-4-oxo-6-[4-(pentafluoro–λ6 sulfanyl)phenyl]-***N***-phenylpiperidine-1-carboxamide (5cC):** According to the general procedure, the reaction of piperidin-4-one **2c** (2.49 mg, 5.69 μmol) in 1,2-DCE (102.5 mM) with **7C** afforded **5cC** (3.22 mg, 5.79 μmol). ¹H NMR (400 MHz, CDCl₃): δ = 7.81-7.75 (m, 2 H), 7.61–7.55 (m, 2 H), 7.25–7.20 (m, 2 H), 7.06–7.02 (m, 3 H), 6.90– 6.86 (m, 2 H), 6.67 (s, 1 H), 6.49–6.47 (m, 1 H), 6.47–6.43 (m, 1 H), 5.16 (dd, J = 11.0, 4.9 Hz, 1 H), 3.89 (s, 3 H), 3.63 (s, 3 H), 3.28 (dd, $J = 18.7, 3.7$ Hz, 1 H), 3.00 (dd, $J = 18.7, 5.9$ Hz, 1 H), 2.77 (dd, $J =$ 17.5, 11.0 Hz, 1 H), 2.66 (dd, $J = 17.5$, 4.9 Hz, 1 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 206.3, 156.6, 153.4 (indirect observation), 150.9, 149.7, 146.9, 138.4, 133.8, 129.1, 127.4, 126.9–126.8 (m), 123.9, 120.1, 118.1, 111.7, 108.3, 57.6, 56.2, 55.9, 51.5, 47.0, 42.4 ppm. FTIR: ν˜ = 3389, 2926, 1725, 1663, 1598, 1518, 1265, 1238, 844 cm–1. **HRMS** [ESI (m/z)] calcd. for $(C_{26}H_{25}F_5N_2O_4S + Na)^+ = 579.13474$, found 579.13534 (|Δ| = 0.1 ppm). *R***F**: 0.22 (heptane/AcOEt, 2:1). **Yield**: 99 %.

(2*S***,6***R***)-***N***-(2-Chlorophenyl)-2-(3,4-dimethoxyphenyl)-6- (4-fluorophenyl)-4-oxopiperidine-1-carboxamide (5aD):** According to the general procedure, the reaction of piperidin-4-one **2a** (2.4 mg, 7.28 μmol) in 1,2-DCE (90.2 mM) with **7D** afforded **5aD** (2.58 mg, 5.34 μmol). ¹ H NMR (400 MHz, CDCl3): *δ* = 8.09 (dd, J = 8.2, 1.5 Hz, 1 H), 7.44–7.37 (m, 2 H), 7.25–7.17 (m, 2 H), 7.11–7.04 (m, 2 H), 7.02 (s, 1 H), 6.98–6.90 (m, 1 H), 6.85 (dd, $J = 8.2$, 1.9 Hz, 1 H), 6.82 (d, $J = 8.2$ Hz, 1 H), 6.73 (d, $J = 1.9$ Hz, 1 H), 6.15 (t, $J =$ 5.6 Hz, 1 H), 5.50 (dd, J = 9.3, 5.1 Hz, 1 H), 3.86 (s, 3 H), 3.75 (s, 3 H), 3.17 (dd, J = 18.3, 5.6 Hz, 1 H), 2.94 (dd, J = 17.7, 9.3 Hz, 1 H),

2.88 (dd, $J = 18.4$, 5.6 Hz, 1 H), 2.73 (dd, $J = 17.7$, 5.1 Hz, 1 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 207.2, 162.3 (d, J = 247.7 Hz), 156.5, 150.2, 149.3, 138.0 (d, J = 3.2 Hz), 135.8, 133.7, 129.0, 128.6 (d, J = 8.1 Hz), 127.5, 124.0, 123.1, 122.3, 118.5, 116.3 (d, J = 21.5 Hz), 111.7, 109.2, 56.2, 56.1, 53.0, 46.2, 43.8 ppm. FTIR: \tilde{v} = 3365, 2931, 1723, 1666, 1510, 1306, 1264, 1026 cm–1. **HRMS** [ESI (m/z)] calcd. for $(C_{26}H_{24}CIFN_2O_4 + Na)^+ = 505.13063$, found 505.13076 ($|\Delta|$ = 0.3 ppm). *R***F**: 0.35 (heptane/AcOEt, 2:1). **Yield**: 73 %.

(2*S***,6***R***)-***N***-(2-Chlorophenyl)-2-(3,4-dimethoxyphenyl)-4-oxo-6- [4-(trifluoromethyl)phenyl]piperidine-1-carboxamide (5bD):** According to the general procedure, the reaction of piperidin-4-one **2b** (1.98 mg, 5.22 μmol) in 1,2-DCE (82.8 mM) with **7D** afforded **5bD** (2.15 mg, 4.03 μmol). ¹H NMR (500 MHz, CDCl₃): δ = 8.09 (dd, J = 8.3, 1.5 Hz, 1 H), 7.67–7.63 (m, 2 H), 7.60–7.56 (m, 2 H), 7.25–7.19 (m, 2 H), 7.04 (s, 1 H), 6.95 (ddd, J = 8.1, 7.4, 1.5 Hz, 1 H), 6.86 (dd, $J = 8.3$, 2.1 Hz, 2 H), 6.82 (d, $J = 8.3$ Hz, 1 H), 6.65 (d, $J = 2.1$ Hz, 1 H), 6.31 (t, $J = 5.4$ Hz, 1 H), 5.43 (dd, $J = 9.7$, 5.1 Hz, 1 H), 3.85 (s, 3 H), 3.70 (s, 3 H), 3.22 (dd, $J = 18.5$, 5.1 Hz, 1 H), 2.94 (dd, $J = 18.5$, 5.7 Hz, 1 H), 2.87 (dd, $J = 17.6$, 9.7 Hz, 1 H), 2.74 (dd, $J = 17.6$, 5.1 Hz, 1 H) ppm. ¹³C NMR (126 MHz, CDCl₃): δ = 206.4, 156.4, 150.2, 149.3, 146.3, 135.6, 133.2, 130.2 (q, J = 32.7 Hz), 128.9, 127.4, 127.2, 126.1 (q, $J = 3.6$ Hz), 124.1, 123.7 (q, $J = 272.5$ Hz, indirect observation), 123.1, 122.2, 118.5, 111.7, 108.8, 56.6, 56.0, 55.9, 52.8, 46.5, 43.0 ppm. FTIR: \tilde{v} = 3356, 2961, 1724, 1666, 1593, 1517, 1439, 1327, 1263, 1234, 1124, 754 cm⁻¹. **HRMS** [ESI (m/z)] calcd. for $(C_{27}H_{24}CH_{3}N_{2}O_{4}$ $+$ Na)⁺ = 555.12689, found 555.12901 ($|\Delta|$ = 2.8 ppm). R **F**: 0.33 (heptane/AcOEt, 2:1). **Yield**: 77 %.

(2*S***,6***R***)-***N***-(2-Chlorophenyl)-2-(3,4-dimethoxyphenyl)-4-oxo-6- [4-(pentafluoro–λ6-sulfanyl)phenyl]piperidine-1-carboxamide (5cD):** According to the general procedure, the reaction of piperidin-4-one **2c** (3.4 mg, 7.77 μmol) in 1,2-DCE (78.5 mM) with **7D** afforded **5cD** (4.6 mg, 7.78 μmol). ¹H NMR (400 MHz, CDCl₃): δ = 8.09–8.05 (m, 1 H), 7.79–7.75 (m, 2 H), 7.58–7.53 (m, 2 H), 7.24–7.20 $(m, 2 H)$, 7.05 (s, 1 H), 6.96 (ddd, $J = 8.2$, 7.3, 1.5 Hz, 1 H), 6.87 (dd, $J = 8.2, 2.1$ Hz, 1 H), 6.83 (d, $J = 8.2$ Hz, 1 H), 6.60 (d, $J = 2.1$ Hz, 1 H), 6.32 (t, $J = 5.4$ Hz, 1 H), 5.40 (dd, $J = 9.7$, 5.1 Hz, 1 H), 3.85 (s, 3 H), 3.68 (s, 3 H), 3.21 (dd, $J = 18.6$, 5.0 Hz, 1 H), 2.94 (dd, $J = 18.6$, 5.8 Hz, 1 H), 2.86 (dd, $J = 17.6$, 9.7 Hz, 1 H), 2.74 (dd, $J = 17.6$, 5.1 Hz, 1 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 206.3, 156.4, 153.3 (indirect observation), 150.4, 149.5, 146.4, 135.6, 133.2, 129.1, 127.6, 127.4, 127.0–126.8 (m), 124.3, 123.2, 122.4, 118.6, 111.8, 108.7, 56.9, 56.2, 56.0, 52.5, 46.7, 42.9 ppm. FTIR: \tilde{v} = 3360, 2961, 2838, 2258, 1725, 1686, 1593, 1517, 1440, 1306, 1263, 1234, 1145, 1027, 842, 751 cm⁻¹. **HRMS** [ESI (m/z)] calcd. for $(C_{26}H_{24}ClF_5N_2O_4S + Na)^+$ = 613.09632, found 613.09446 (|Δ| = 3.02 ppm). **Yield**: 99 %.

(2*S***,6***R***)-***N***-(2,4-Difluorophenyl)-2-(3,4-dimethoxyphenyl)-6-(4 fluorophenyl)-4-oxopiperidine-1-carboxamide (5aE):** According to the general procedure, the reaction of piperidin-4-one **2a** (2.30 mg, 6.98 μmol) in 1,2-DCE (87.6 mM) with **7E** afforded **5aE** (3.28 mg, 6.77 μmol). ¹H NMR (400 MHz, CDCl₃): δ = 8.01 (td, J = 9.1, 5.9 Hz, 1 H), 7.42–7.35 (m, 2 H), 7.12–7.05 (m, 2 H), 6.86–6.77 (m, 3 H), 6.74–6.67 (m, 2 H), 6.64 (d, $J = 1.8$ Hz, 1 H), 6.15 (t, $J =$ 5.4 Hz, 1 H), 5.37 (dd, J = 9.9, 4.9 Hz, 1 H), 3.87 (s, 3 H), 3.72 (s, 3 H), 3.20 (dd, $J = 18.5$, 5.1 Hz, 1 H), 2.91 (dd, $J = 17.7$, 9.9 Hz, 1 H), 2.88 (dd, $J = 18.5$, 5.6 Hz, 1 H), 2.68 (dd, $J = 17.7$, 4.9 Hz, 1 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 207.0, 162.3 (d, J = 248.0 Hz), 158.2 $(dd, J = 245.2, 11.4 Hz$, 156.4, 152.6 (dd, $J = 246.0, 12.0 Hz$), 150.3, 149.4, 138.1 (d, $J = 3.3$ Hz), 133.6, 128.6 (d, $J = 8.1$ Hz), 123.5 (dd, $J = 10.4$, 3.8 Hz), 122.7 (dd, $J = 9.0$, 2.4 Hz), 118.3, 116.3 (d, $J =$ 21.5 Hz), 111.7, 111.1 (dd, $J = 21.6$, 3.7 Hz), 108.9, 103.4 (dd, $J =$ 26.7, 23.3 Hz), 56.5, 56.10, 56.06, 52.6, 46.2, 43.4 ppm. FTIR: $\tilde{v} =$ 3379, 2936, 1721, 1665, 1534, 1511, 1256, 1228, 1025, 962, 849 cm–1. **HRMS** [ESI (m/z)] calcd. for $(C_{26}H_{23}F_{3}N_{2}O_{4} + Na)^{+} = 507.15021$, found 507.15113 ($|\Delta|$ = 0.7 ppm). R_F : 0.29 (heptane/AcOEt, 2:1). **Yield**: 97 %.

(2*S***,6***R***)-***N***-(2,4-Difluorophenyl)-2-(3,4-dimethoxyphenyl)-4-oxo-6-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide (5bE):** According to the general procedure, the reaction of piperidin-4-one **2b** (1.37 mg, 3.61 μmol) in 1,2-DCE (82.8 mM) with **7E** afforded **5bE** (1.07 g, 2.00 μmol). ¹H NMR (400 MHz, CDCl₃): δ = 8.01 (td, J = 9.1, 5.9 Hz, 1 H), 7.70–7.64 (m, 2 H), 7.60–7.55 (m, 2 H), 6.88–6.79 (m, 3 H), 6.73 (s, 1 H), 6.72 (ddd, $J = 11.0$, 8.3, 2.8 Hz, 1 H), 6.54–6.52 (m, 1 H), 6.35 (t, $J = 5.1$ Hz, 1 H), 5.26 (dd, $J = 10.5$, 4.9 Hz, 1 H), 3.86 (s, 3 H), 3.66 (s, 3 H), 3.27 (dd, $J = 18.6$, 4.4 Hz, 1 H), 2.95 (dd, $J = 18.6$, 5.8 Hz, 1 H), 2.82 (dd, $J = 17.6$, 10.6 Hz, 1 H), 2.67 (dd, $J = 17.6$, 4.9 Hz, 1 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 206.5, 156.4, 158.2 $(d, J = 244.4 \text{ Hz})$, 152.3 $(dd, J = 243.9, 11.6 \text{ Hz})$, 150.5, 149.6, 146.5, 133.2, 130.2 (indirect observation), 127.4, 126.2 (q, J = 3.5 Hz), 123.8 (g, $J = 270.3$ Hz, indirect observation), 123.4 (dd, $J = 10.4$, 3.9 Hz), 122.8 (dd, $J = 8.8$, 2.3 Hz), 118.4, 111.8, 111.2 (dd, $J = 21.6$, 3.8 Hz), 108.5, 103.5 (dd, J = 26.6, 23.3 Hz), 57.2, 56.1, 56.0, 52.3, 46.7, 42.7 ppm. FTIR: \tilde{v} = 3381, 2927, 1723, 1667, 1611, 1535, 1518, 1327, 1257, 1126, 1026 cm⁻¹. **HRMS** [ESI (*m*/z)] calcd. for $(C_{27}H_{23}F_5N_2O_4 + Na)^+$ = 557.14702, found 557.14825 (|Δ| = 1.2 ppm). *R***F**: 0.31 (heptane/ AcOEt, 2:1). **Yield**: 55 %.

(2*S***,6***R***)-***N***-(2,4-Difluorophenyl)-2-(3,4-dimethoxyphenyl)-4-oxo-6-[4-(pentafluoro–λ6-sulfanyl)phenyl]piperidine-1-carboxamide (5cE):** According to the general procedure, the reaction of piperidin-4-one **2c** (1.87 mg, 4.27 μmol) in 1,2-DCE (82.9 mM) with **7E** afforded **5cE** (2.2 mg, 3.7 µmol). ¹H NMR (400 MHz, CDCl₃): δ = 8.00 (td, J = 9.1, 5.9 Hz, 1 H), 7.83–7.74 (m, 2 H), 7.60–7.52 (m, 2 H), 6.88–6.80 (m, 3 H), 6.79–6.68 (m, 2 H), 6.49 (d, $J = 1.2$ Hz, 1 H), 6.38 (t, $J =$ 5.0 Hz, 1 H), 5.22 (dd, J = 10.7, 4.9 Hz, 1 H), 3.87 (s, 3 H), 3.65 (s, 3 H), 3.27 (dd, $J = 18.6$, 4.1 Hz, 1 H), 2.97 (dd, $J = 18.6$, 5.8 Hz, 1 H), 2.80 (dd, $J = 17.6$, 10.7 Hz, 1 H), 2.68 (dd, $J = 17.6$, 4.9 Hz, 1 H) ppm. ¹³C NMR (126 MHz, CDCl₃): δ = 206.2, 158.3 (dd, J = 245.7, 11.4 Hz), 156.4, 153.5–153.1 (m), 152.7 (dd, J = 245.7, 11.5 Hz), 150.6, 149.7, 146.5, 133.1, 127.4, 127.0–126.9 (m), 123.4 (dd, J = 10.5, 3.7 Hz), 122.9 (dd, $J = 9.0$, 2.5 Hz), 118.4, 111.8, 111.2 (dd, $J = 21.7$, 3.6 Hz), 108.3, 103.5 (dd, J = 26.6, 23.3 Hz), 57.4, 56.2, 55.9, 51.9, 46.9, 42.5 ppm. FTIR: \tilde{v} = 3376, 2962, 1725, 1666, 1610, 1534, 1517, 1257, 843 cm⁻¹. **HRMS** [ESI (*m*/z)] calcd. for $(C_{26}H_{23}F_7N_2O_4S + H)^+ = 593.13395$, found 593.13686 ($|\Delta|$ = 4.0 ppm). **HRMS** [ESI (*m*/z)] calcd. for $(C_{26}H_{23}F_7N_2O_4S + Na)^+ = 615.11590$, found 615.11657 ($|\Delta|$ = 0.2 ppm). *R***F**: 0.25 (heptane/AcOEt, 2:1). **Yield**: 87 %.

Synthesis and Full Characterization of Amino Alcohols 11 and 12

(2*S***,4***R***,6***R***)-2-(3,4-Dimethoxyphenyl)-6-[4-(pentafluoro–λ6 sulfanyl)phenyl]piperidin-4-ol (11):** Solution A: piperidin-4-one **2c** (8.4 mg, 0.019 mmol) dissolved in THF (50.3 mm). Solution B: LiBH₄ (2 M solution in THF; 1.5 equiv.) dissolved in THF (75 mM). Solution A (13.33 μL/min) was combined with B (20 μL/min) inside the glass microreactor (internal volume: 100 μL). The reaction was performed at 21 °C for 3 min. ¹H NMR (500 MHz, CDCl₃): δ = 7.75–7.69 (m, 2 H), $7.57 - 7.52$ (m, 2 H), 7.00 (d, $J = 2.0$ Hz, 1 H), 6.96 (dd, $J = 8.2$, 2.0 Hz, 1 H), 6.83 (d, J = 8.2 Hz, 1 H), 3.99–3.92 (m, 2 H), 3.91 (s, 3 H), 3.87 (s, 3 H), 3.81 (dd, $J = 11.3$, 2.4 Hz, 1 H), 2.21-2.10 (m, 2 H), 1.62–1.46 (m, 2 H) ppm. ¹³C NMR (126 MHz, CDCl₃): δ = 153.0 (indirect observation), 149.2, 148.5, 148.2, 136.7, 127.2, 126.3 (quint, J = 4.0 Hz), 118.9, 111.2, 110.1, 69.9, 59.7, 59.4, 56.09, 56.07, 43.9, 43.8 ppm. FTIR: \tilde{v} = 2936, 2839, 1517, 1262, 1232, 1027, 845, 815 cm⁻¹. **HRMS** [ESI (*m*/z)] calcd. for $(C_{19}H_{22}F_5NO_3S + H)^+ = 440.13188$, found 440.13125 (|Δ| = 1.44 ppm). **Yield**: 76 %.

(2*S***,4***S***,6***R***)-2-(3,4-Dimethoxyphenyl)-6-[4-(trifluoromethyl) phenyl]piperidin-4-ol (12):** N-Selectride (3.95 mL, 3.95 mmol, 1.0 M solution in THF) was added to a solution of piperidin-4-one **2b** (500 mg, 1.32 mmol) in dry THF (96 mL) at –78 °C. The reaction was stirred for 1 h and it was quenched with H_2O (100 mL). The solution was allowed to reach 21 °C and then AcOEt was added. The organic layer was separated and the aqueous layer was extracted with AcOEt (3×50 mL). The combined organic layers were washed with brine, dried with anhydrous $Na₂SO₄$, filtered off and concentrated in vacuo. The residue was purified by SCX-2 column to afford amino alcohol **12** (456 mg, 1.20 mmol). ¹H NMR (400 MHz, CDCl₃): δ = 7.66–7.53 (m, 4 H), 7.04–6.97 (m, 2 H), 6.84 (d, $J = 8.1$ Hz, 1 H), 4.40– 4.32 (m, 2 H), 4.25 (dd, J = 11.7, 2.7 Hz, 1 H), 3.91 (s, 3 H), 3.87 (s, 3 H), 1.95-1.87 (m, 2 H), 1.86-1.70 (m, 2 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 149.4, 149.1, 148.4, 137.5 (indirect observation), 129.4 (indirect observation), 127.3, 125.5 (q, $J = 3.7$ Hz), 123.0 (indirect observation), 118.9, 111.3, 110.2, 66.2, 56.09, 56.07, 56.0, 55.7, 41.66, 41.65 ppm. FTIR: \tilde{v} = 2936, 1517, 1465, 1326, 1263, 1163, 1123, 1067, 1027, 806 cm⁻¹. **HRMS** [ESI (*m*/z)] calcd. for $(C_{20}H_{22}F_3NO_3 + H)^+$ = 382.16300, found 382.16336 (|Δ| = 0.94 ppm). **Yield**: 91 %.

Synthesis and Full Characterization of Alkyl Ureas 6a–c: Solution A: compound **11** (1.0 equiv.) dissolved in tBuOH (94.3–96.5 mM). Solution B: alkyl isocyanate (**7A**, **7B** or **7F**, 1.5 equiv.) dissolved in tBuOH (0.1 M). Solution A (2.35 μL/min) was combined with B (3.53 μL/min) inside the glass microreactor (internal volume: 100 μL). The reaction was performed at 50 °C for 17 min.

(2*S***,4***R***,6***R***)-2-(3,4-Dimethoxyphenyl)-***N***-ethyl-4-hydroxy-6-[4- (pentafluoro–λ6-sulfanyl)phenyl]piperidine-1-carboxamide (6a):** According to the general procedure, the reaction of amino alcohol 11 (2.37 mg, 5.39 μmol) in tBuOH (94.6 mm) afforded urea **6a** (2.33 mg, 4.56 μmol). ¹H NMR (400 MHz, CDCl₃): δ = 7.74–7.70 $(m, 2 H)$, 7.70–7.65 $(m, 2 H)$, 6.85 $(dd, J = 8.3, 2.0 Hz, 1 H)$, 6.81 $(d,$ $J = 8.3$ Hz, 1 H), 6.57 (d, $J = 2.0$ Hz, 1 H), 5.39 (t, $J = 6.2$ Hz, 1 H), 4.43 (t, $J = 5.8$ Hz, 1 H), 4.40 (dd, $J = 11.7$, 4.3 Hz, 1 H), 4.27-4.14 (m, 1 H), 3.86 (s, 3 H), 3.69 (s, 3 H), 2.93 (qd, J = 7.3, 5.4 Hz, 2 H), 2.43 (dt, $J = 13.3$, 6.2 Hz, 1 H), 2.24-2.10 (m, 2 H), 1.94 (dt, $J = 13.5$, 11.2 Hz, 1 H), 1.78 (d, $J = 3.7$ Hz, 1 H) ppm. ¹³C NMR (101 MHz, CDCl3): *δ* = 160.7, 152.7 (indirect observation), 149.9, 148.9, 148.7 (indirect observation), 135.7, 128.1, 126.3–126.1 (m), 118.7, 111.4, 109.5, 65.8, 59.2, 56.1, 56.0, 55.3, 41.2, 37.8, 35.7, 14.8 ppm. FTIR: \tilde{v} = 3414, 2937, 1627, 1517, 1263, 1140, 1027, 846, 594 cm⁻¹, **HRMS** [ESI (*m*/z)] calcd. for $(C_{22}H_{27}F_5N_2O_4S + Na)^+ = 533.15094$, found 533.15027 (|Δ| = 1.26 ppm). **Yield**: 85 %.

(2*S***,4***R***,6***R***)-2-(3,4-Dimethoxyphenyl)-4-hydroxy-***N***-isopropyl-6- [4-(pentafluoro–λ6-sulfanyl)phenyl]piperidine-1-carboxamide (6b):** According to the general procedure, the reaction of amino alcohol **11** (2.80 mg, 6.37 μmol) in tBuOH (94.3 mM) afforded urea **6b** (2.76 mg, 5.34 μ mol). ¹H NMR (400 MHz, CDCl₃): δ = 7.73–7.68 (m, 2 H), 7.68–7.63 (m, 2 H), 6.86 (dd, J = 8.3, 2.0 Hz, 1 H), 6.81 (d, $J = 8.2$ Hz, 1 H), 6.62 (d, $J = 2.1$ Hz, 1 H), 5.19 (dd, $J = 7.4$, 5.1 Hz, 1 H), 4.36–4.28 (m, 2 H), 4.24–4.12 (m, 1 H), 3.86 (s, 3 H), 3.72 (s, 3 H), 3.60–3.50 (m, 1 H), 2.46–2.35 (m, 1 H), 2.21–2.08 (m, 2 H), 1.99–1.87 (m, 1 H), 0.75 (d, $J = 6.5$ Hz, 3 H), 0.61 (d, $J = 6.5$ Hz, 3 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 160.3, 152.7 (indirect observation), 149.8, 148.9, 148.4, 135.5, 128.2, 126.2–126.0 (m), 119.0, 111.4, 109.9, 66.2, 59.7, 56.2, 56.0, 42.4, 41.4, 38.4, 22.8, 22.5 ppm. FTIR: $\tilde{v} = 3404$, 2967, 1704, 1627, 1517, 1465, 1263, 1140, 1027, 844, 595 cm–1. **HRMS** [ESI (*m*/z)] calcd. for $(C_{23}H_{29}F_5N_2O_4S + H)^+ = 525.18464$, found 525.18665 (|Δ| = 3.82 ppm). **Yield**: 84 %.

(2*S***,4***R***,6***R***)-***N***-Benzyl-2-(3,4-dimethoxyphenyl)-4-hydroxy-6-[4- (pentafluoro–λ6-sulfanyl)phenyl]piperidine-1-carboxamide (6c):** According to the general procedure, the reaction of amino alcohol **11** (2.00 mg, 4.55 μmol) in tBuOH (96.5 mM) afforded urea **6c** (2.60 mg, 4.54 μmol). ¹ H NMR (400 MHz, CDCl3): *δ* = 7.76–7.66 (m, 4 H), 7.21–7.12 (m, 3 H), 6.80 (dd, $J = 8.2$, 2.1 Hz, 1 H), 6.77–6.72 (m, 3 H), 6.54 (d, $J = 2.1$ Hz, 1 H), 5.44 (t, $J = 6.1$ Hz, 1 H), 4.80 (t, $J =$ 5.6 Hz, 1 H), 4.47 (dd, $J = 11.5$, 4.2 Hz, 1 H), 4.27-4.19 (m, 1 H), 4.17 $(dd, J = 14.8, 5.8$ Hz, 1 H), 4.05 $(dd, J = 14.8, 5.2$ Hz, 1 H), 3.85 $(s, 3)$ H), 3.63 (s, 3 H), 2.44 (dt, $J = 13.1$, 6.3 Hz, 1 H), 2.24 (dt, $J = 14.4$, 6.5 Hz, 1 H), 2.15 (dt, $J = 13.5$, 5.1 Hz, 1 H), 1.97 (dt, $J = 13.7$, 11.1 Hz, 1 H), 1.82 (d, $J = 3.3$ Hz, 1 H) ppm. ¹³C NMR (101 MHz, CDCl₃): $\delta =$ 160.5, 152.6 (indirect observation), 149.9, 148.9, 148.7, 138.4, 135.6, 128.5, 128.2, 127.3, 127.2, 126.3–126.2 (m), 118.7, 111.5, 109.4, 65.6, 59.0, 56.1, 55.9, 55.2, 45.1, 40.9, 37.6 ppm. FTIR: $\tilde{\text{v}} = 3410$, 2936, 1690, 1560, 1541, 1263, 1139, 1027, 842, 750, 595 cm–1. **HRMS** [ESI (m/z)] calcd. for $(C_{27}H_{29}F_5N_2O_4S + Na)^+ = 595.16659$, found 595.16478 (|Δ| = 3.04 ppm). **Yield**: 99 %.

Synthesis and Full Characterization of Aryl Ureas 6d and 6e: Solution A: compound **11** (1.0 equiv.) dissolved in 1,2-DCE (95.6– 105.0 mM). Solution B: aryl isocyanate (**7C**–**E**, 1.1 equiv.) dissolved in 1,2-DCE (0.1 M). Solution A (2.80 μL/min) was combined with B (3.08 μL/min) inside the glass microreactor (internal volume: 100 μL). The reaction was performed at 80 °C for 17 min.

(2*S***,4***R***,6***R***)-2-(3,4-Dimethoxyphenyl)-4-hydroxy-6-[4-(pentafluoro–λ6-sulfanyl)phenyl]-***N***-phenylpiperidine-1-carboxamide (6d):** According to the general procedure, the reaction of amino alcohol **11** (2.57 mg, 5.85 μmol) in 1,2-DCE (95.6 mM) afforded urea **6d** (3.26 mg, 5.84 μmol). ¹H NMR (400 MHz, CDCl₃): δ = 7.80-7.76 (m, 2 H), 7.75–7.70 (m, 2 H), 7.20–7.14 (m, 2 H), 6.99–6.90 (m, 4 H), 6.87 (d, $J = 8.2$ Hz, 1 H), 6.56 (s, 1 H), 6.51 (d, $J = 2.1$ Hz, 1 H), 5.80 $(t, J = 5.8$ Hz, 1 H), 4.61 (dd, $J = 12.0$, 4.3 Hz, 1 H), 4.36-4.24 (m, 1 H), 3.88 (s, 3 H), 3.62 (s, 3 H), 2.58 (dt, $J = 14.3$, 6.9 Hz, 1 H), 2.37 (dt, $J = 14.9$, 5.4 Hz, 1 H), 2.18 (dt, $J = 13.6$, 5.1 Hz, 1 H), 2.03 (dt, $J = 13.7, 11.6$ Hz, 1 H), 1.89-1.85 (m, 1 H) ppm. ¹³C NMR (101 MHz, CDCl3): *δ* = 157.6, 152.6 (indirect observation), 150.4, 149.3, 148.9, 138.5, 135.3, 129.0, 128.2, 126.4–126.2 (m), 123.6, 119.8, 118.5, 111.6, 109.1, 65.1, 59.1, 56.2, 55.9, 53.8, 41.0, 36.6 ppm. FTIR: $\tilde{v} = 3388$, 2933, 2841, 1686, 1647, 1501, 1443, 1420, 1264, 1237, 1140, 1027, 843, 754 cm⁻¹. **HRMS** [ESI (*m*/z)] calcd. for $(C_{26}H_{27}F_5N_2O_4S + Na)^+$ = 581.15094, found 581.14995 (|Δ| = 1.70 ppm). **Yield**: 99 %.

(2*S***,4***R***,6***R***)-***N***-(2-Chlorophenyl)-2-(3,4-dimethoxyphenyl)-4 hydroxy-6-[4-(pentafluoro–λ6-sulfanyl)phenyl]piperidine-1 carboxamide (6e):** According to the general procedure, the reaction of amino alcohol **11** (3.40 mg, 7.74 μmol) in 1,2-DCE (105.0 mM) afforded urea 6e (3.81 mg, 6.42 μmol). ¹H NMR (400 MHz, CDCl₃): *δ* = 8.01 (dd, J = 8.6, 1.6 Hz, 1 H), 7.79–7.75 (m, 2 H), 7.75–7.70 (m, 2 H), 7.21–7.14 (m, 2 H), 6.97 (s, 1 H), 6.95–6.87 (m, 2 H), 6.82 (d, J = 8.3 Hz, 1 H), 6.61 (d, $J = 2.2$ Hz, 1 H), 5.83 (t, $J = 6.0$ Hz, 1 H), 4.85 $(dd, J = 11.1, 4.8$ Hz, 1 H), 4.39-4.37 (m, 1 H), 3.84 (s, 3 H), 3.65 (s, 3 H), 2.57 (dt, J = 14.4, 7.0 Hz, 1 H), 2.36 (dt, J = 14.9, 5.8 Hz, 1 H), 2.26 (dt, $J = 13.9$, 5.4 Hz, 1 H), 2.09 (dt, $J = 13.9$, 10.5 Hz, 1 H), 1.87 (d, $J = 3.6$ Hz, 1 H) ppm. ¹³C NMR (101 MHz, CDCl₃): $\delta = 157.1$, 152.6 (indirect observation), 150.1, 149.1, 148.5, 135.8, 134.8, 129.0, 128.2, 127.5, 126.5–126.3 (m), 123.9, 123.0, 122.0, 119.0, 111.8, 109.2, 64.9, 58.3, 56.2, 56.0, 54.0, 40.8, 36.6 ppm. FTIR: \tilde{v} = 3362, 2936, 2838, 2258, 1735, 1663, 1517, 1439, 1263, 1140, 1027, 843, 754 cm–1. **HRMS** [ESI (*m*/z)] calcd. for $(C_{26}H_{26}ClF_5N_2O_4S + H)^+ = 593.13002$, found 593.12885 (|Δ| = 1.98 ppm). **Yield**: 83 %.

Synthesis and Full Characterization of Ureas 13a and 13b

(2*S***,4***S***,6***R***)-2-(3,4-Dimethoxyphenyl)-4-hydroxy-***N***-isopropyl-6- [4-(trifluoromethyl)phenyl]piperidine-1-carboxamide 13a and 13b:** Isopropyl isocyanate (**7B**; 0.01 mL, 0.12 mmol) was added to a solution of piperidin-4-ol **12** (46.2 mg, 0.12 mmol) in CH_2Cl_2

(1.2 mL) at 21 °C and the reaction was stirred for 20 h. The solvent was removed under vacuo and the crude was purified by column chromatography (CH₂Cl₂ \rightarrow CH₂Cl₂/MeOH, 10:1) to afford compounds **13a** and **13b** (21.5 mg, 0.046 mmol). **Combined yield**: 38 %.

13a: ¹H NMR (400 MHz, CDCl₃): δ = 7.59–7.49 (m, 4 H), 6.84–6.74 (m, 2 H), 6.64 (br. s, 1 H), 5.65 (t, $J = 5.4$ Hz, 1 H), 4.90 (dd, $J = 10.0$, 4.1 Hz, 1 H), 4.43 (quint, $J = 5.2$ Hz, 1 H), 4.33 (d, $J = 7.4$ Hz, 1 H), 3.83 (s, 3 H), 3.82–3.71 (m, 1 H), 3.71 (s, 3 H), 2.76–2.64 (m, 1 H), 2.15–2.07 (m, 1 H), 2.00 (dt, $J = 15.0$, 5.4 Hz, 1 H), 1.84 (dt, $J = 14.9$, 3.8 Hz, 1 H), 0.89 (d, $J = 6.5$ Hz, 3 H), 0.74 (d, $J = 6.4$ Hz, 3 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 159.3, 149.7, 148.65-148.59 (m), 148.5, 136.1, 129.2 (q, $J = 32.6$ Hz), 127.4, 125.5 (q, $J = 3.7$ Hz), 122.8 (indirect observation), 118.3, 111.3, 109.6, 62.4, 56.0, 55.9, 54.1, 52.1, 42.8, 39.6, 36.1, 23.2, 22.9 ppm. FTIR: \tilde{v} = 3415, 2965, 2937, 1619, 1517, 1465, 1327, 1262, 1164, 1123, 1070, 1019, 808 cm–1. **HRMS** [ESI (*m*/z)] calcd. for $(C_{24}H_{29}F_3N_2O_4 + Na)^+$ = 489.19771, found 489.19701 ($|\Delta|$ = 1.43 ppm).

13b: ¹H NMR (400 MHz, CDCl₃): δ = 7.69–7.62 (m, 2 H), 7.61–7.54 $(m, 2 H)$, 6.90–6.84 $(m, 1 H)$, 6.81 $(dd, J = 8.2, 0.8 Hz, 1 H)$, 6.67 $(d,$ $J = 1.9$ Hz, 1 H), 5.12 (dd, $J = 7.3$, 5.2 Hz, 1 H), 4.36 (dd, $J = 11.7$, 3.9 Hz, 1 H), 4.32 (d, J = 7.5 Hz, 1 H), 4.23–4.11 (m, 1 H), 3.86 (s, 3 H), 3.73 (s, 3 H), 3.60–347 (m, 1 H), 2.41–2.33 (m, 1 H), 2.20–2.10 (m, 2 H), 2.01-1.91 (m, 1 H), 0.72 (d, $J = 5.9$ Hz, 3 H), 0.61 (d, $J = 6.6$ Hz, 3 H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 160.4, 149.7, 148.8, 148.4, 135.6, 129.4 (indirect observation), 128.2, 125.4, 122.9 (indirect observation), 119.1, 111.3, 110.0, 66.3, 59.6, 56.7, 56.1, 56.0, 42.4, 41.2, 38.7, 22.8, 22.5 ppm. FTIR: \tilde{v} = 3414, 2930, 1620, 1517, 1465, 1325, 1263, 1164, 1122, 1027, 842 cm–1. **HRMS** [ESI (m/z)] calcd. for $(C_{24}H_{29}F_3N_2O_4 + Na)^+ = 489.19771$, found 489.19688 ($|\Delta| =$ 1.70 ppm).

Acknowledgments

This work has been supported by the FP7 Marie Curie Actions of the European Commission through the ITN ECHONET Network (MCITN-2012-316379).

Keywords: Continuous flow · Nitrogen heterocycles · Atropisomers · Nitrogen heterocycles · Compound Libraries

[2] A. D. Jagtap, N. B. Kondekar, A. A. Sadani, J. W. Chern, Curr. Med. Chem. **2017**, 24, 622–651.

- [3] E. Kühle, E. Klauke, Angew. Chem. Int. Ed. Engl. **1977**, 16, 735–806; Angew. Chem. **1977**, 89, 797.
- [4] G. Theodoridis in Fluorine and the Environment, Vol. 2 (Ed.: A. Tressaud), Elsevier, Oxford, **2006**, pp. 121–175.
- [5] F. M. Sabbatini, R. Di Fabio, C. Griffante, G. Pentassuglia, L. Zonzini, S. Melotto, G. Alvaro, A. M. Capelli, L. Pippo, E. Perdona, Y. St. Denis, S. Costa, M. Corsi, Bioorg. Med. Chem. Lett. **2010**, 20, 623–627.
- [6] A. Riesco-Domínguez, N. van der Zwaluw, D. Blanco-Ania, F. P. J. T. Rutjes, Eur. J. Org. Chem. **2017**, 2017, 662–670.
- [7] a) E. P. Gillis, K. J. Eastman, M. D. Hill, D. J. Donnelly, N. A. Meanwell, J. Med. Chem. **2015**, 58, 8315–8359; b) V. De Matteis, F. L. van Delft, J. Tiebes, F. P. J. T. Rutjes, Eur. J. Org. Chem. **2006**, 1166–1176.
- [8] a) A. Gioiello, E. Rosatelli, M. Teofrasti, P. Filipponi, R. Pellicciari, ACS Comb. Sci. **2013**, 15, 235–239; b) P. P. Lange, K. James, ACS Comb. Sci. **2012**, 14, 570–578; c) M. Baumann, I. R. Baxendale, C. Kuratli, S. V. Ley, R. E. Martin, J. Schneider, ACS Comb. Sci. **2011**, 13, 405–413.
- [9] Reactions were carried out using the FlowStart Evo equipment and microreactors purchased from FutureChemistry [\(futurechemistry.com](futurechemistry.com) accessed Sep 11, **2017**).
- [10] 1,3-Diethylurea was obtained as a side product in the reaction mixture (ratio **5cA**/1,3-diethylurea 1:0.28).
- [11] The presence of 1,3-diethylurea present was reduced (ratio **5cA**/1,3-diethylurea 1:0.1).
- [12] At very low flow rates, stabilization and pressure of the equipment may take long; therefore, a stabilization time is calculated and run before the collecting product fraction. The stabilization time is calculated in Equation (1), experimental section.
- [13] a) M. Hutchby in Novel Synthetic Chemistry of Ureas and Amides, Springer, Berlin Heidelberg, **2013**, pp. 57–70; b) M. Hutchby, C. E. Houlden, J. G. Ford, S. N. G. Tyler, M. R. Gagn, G. C. Lloyd-Jones, K. I. Booker-Milburn, Angew. Chem. Int. Ed. **2009**, 48, 8721–8724; Angew. Chem. **2009**, 121, 8877.
- [14] S. R. Neufeldt, G. Jimenez-Oses, D. L. Comins, K. N. Houk, J. Org. Chem. **2014**, 79, 11609–11618.
- [15] The reduction of ketone **2** to alcohol **12** was unsuccessfully performed in flow.
- [16] 1,3-Dibenzylurea was present in the reaction mixture (ratio **6c**/1,3-dibenzylurea 1:0.15).
- [17] L. Y. Vargas Méndez, V. V. Kouznetsov, Cent. Eur. J. Chem. **2011**, 9, 877– 885.
- [18] We do not rule out the possibility of a mixture of rotamers because the ¹³C NMR chemical shift of the carbamoyl carbon is δ = 159.3 ppm and the IR stretching frequency of the C=O is at 1619 cm^{-1} in the IR (higher values would be expected if atropisomers were observed, although the absence of examples of this phenomenon in the literature makes the prediction of those values difficult).
- [19] Compounds **13a** and **13b** were isolated after column chromatography of the reaction in batch of amino alcohol **12** and isopropyl isocyanate **7B**.

Received: November 5, 2017

^[1] I. Gallou, Org. Prep. Proced. Int. **2007**, 39, 355–383.